222 related articles for article (PubMed ID: 24401833)
1. Pharmacogenomic characterization of gemcitabine response--a framework for data integration to enable personalized medicine.
Harris M; Bhuvaneshwar K; Natarajan T; Sheahan L; Wang D; Tadesse MG; Shoulson I; Filice R; Steadman K; Pishvaian MJ; Madhavan S; Deeken J
Pharmacogenet Genomics; 2014 Feb; 24(2):81-93. PubMed ID: 24401833
[TBL] [Abstract][Full Text] [Related]
2. A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303.
Innocenti F; Owzar K; Cox NL; Evans P; Kubo M; Zembutsu H; Jiang C; Hollis D; Mushiroda T; Li L; Friedman P; Wang L; Glubb D; Hurwitz H; Giacomini KM; McLeod HL; Goldberg RM; Schilsky RL; Kindler HL; Nakamura Y; Ratain MJ
Clin Cancer Res; 2012 Jan; 18(2):577-84. PubMed ID: 22142827
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine and arabinosylcytosin pharmacogenomics: genome-wide association and drug response biomarkers.
Li L; Fridley BL; Kalari K; Jenkins G; Batzler A; Weinshilboum RM; Wang L
PLoS One; 2009 Nov; 4(11):e7765. PubMed ID: 19898621
[TBL] [Abstract][Full Text] [Related]
4. Genetic variations associated with gemcitabine treatment outcome in pancreatic cancer.
Li L; Zhang JW; Jenkins G; Xie F; Carlson EE; Fridley BL; Bamlet WR; Petersen GM; McWilliams RR; Wang L
Pharmacogenet Genomics; 2016 Dec; 26(12):527-537. PubMed ID: 27749787
[TBL] [Abstract][Full Text] [Related]
5. Contribution of FKBP5 genetic variation to gemcitabine treatment and survival in pancreatic adenocarcinoma.
Ellsworth KA; Eckloff BW; Li L; Moon I; Fridley BL; Jenkins GD; Carlson E; Brisbin A; Abo R; Bamlet W; Petersen G; Wieben ED; Wang L
PLoS One; 2013; 8(8):e70216. PubMed ID: 23936393
[TBL] [Abstract][Full Text] [Related]
6. Targeting cMET with INC280 impairs tumour growth and improves efficacy of gemcitabine in a pancreatic cancer model.
Brandes F; Schmidt K; Wagner C; Redekopf J; Schlitt HJ; Geissler EK; Lang SA
BMC Cancer; 2015 Feb; 15():71. PubMed ID: 25884642
[TBL] [Abstract][Full Text] [Related]
7. Relevance of Sp Binding Site Polymorphism in WWOX for Treatment Outcome in Pancreatic Cancer.
Schirmer MA; Lüske CM; Roppel S; Schaudinn A; Zimmer C; Pflüger R; Haubrock M; Rapp J; Güngör C; Bockhorn M; Hackert T; Hank T; Strobel O; Werner J; Izbicki JR; Johnsen SA; Gaedcke J; Brockmöller J; Ghadimi BM
J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26857392
[TBL] [Abstract][Full Text] [Related]
8. The vitamin D receptor gene as a determinant of survival in pancreatic cancer patients: Genomic analysis and experimental validation.
Innocenti F; Owzar K; Jiang C; Etheridge AS; Gordân R; Sibley AB; Mulkey F; Niedzwiecki D; Glubb D; Neel N; Talamonti MS; Bentrem DJ; Seiser E; Yeh JJ; Van Loon K; McLeod H; Ratain MJ; Kindler HL; Venook AP; Nakamura Y; Kubo M; Petersen GM; Bamlet WR; McWilliams RR
PLoS One; 2018; 13(8):e0202272. PubMed ID: 30107003
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetics in pancreatic cancer.
Tourkantonis IS; Peponi E; Syrigos KN; Saif MW
JOP; 2014 Jul; 15(4):335-9. PubMed ID: 25076337
[TBL] [Abstract][Full Text] [Related]
10. Gemcitabine doublets in advanced pancreatic cancer: should we move on?
Rocha Lima CM; Flores AM
J Clin Oncol; 2006 Jan; 24(3):327-9. PubMed ID: 16344312
[No Abstract] [Full Text] [Related]
11. Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines.
Giovannetti E; Mey V; Danesi R; Mosca I; Del Tacca M
Clin Cancer Res; 2004 May; 10(9):2936-43. PubMed ID: 15131028
[TBL] [Abstract][Full Text] [Related]
12. CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells.
Hong SP; Wen J; Bang S; Park S; Song SY
Int J Cancer; 2009 Nov; 125(10):2323-31. PubMed ID: 19598259
[TBL] [Abstract][Full Text] [Related]
13. Prediction of a side effect and efficacy of adjuvant chemotherapy with gemcitabine for post operative patient of pancreatic cancer by a genetic polymorphism analysis.
Kasuya K; Tsuchida A; Nagakawa Y; Suzuki Y; Suzuki M; Aoki T; Abe Y; Shimazu M; Itoi T; Sofuni A
Hepatogastroenterology; 2012; 59(117):1609-13. PubMed ID: 22155850
[TBL] [Abstract][Full Text] [Related]
14. Integrating pharmacogenetics into gemcitabine dosing--time for a change?
Ciccolini J; Mercier C; Dahan L; André N
Nat Rev Clin Oncol; 2011 Feb; 8(7):439-44. PubMed ID: 21304503
[TBL] [Abstract][Full Text] [Related]
15. Interdependence of gemcitabine treatment, transporter expression, and resistance in human pancreatic carcinoma cells.
Hagmann W; Jesnowski R; Löhr JM
Neoplasia; 2010 Sep; 12(9):740-7. PubMed ID: 20824050
[TBL] [Abstract][Full Text] [Related]
16. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
[TBL] [Abstract][Full Text] [Related]
17. Relationship between single nucleotide polymorphisms in the deoxycytidine kinase gene and chemosensitivity of gemcitabine in six pancreatic cancer cell lines.
Si S; Liao Q; Zhao YP; Hu Y; Zhang Q; You LL
Chin Med J (Engl); 2011 Feb; 124(3):419-22. PubMed ID: 21362344
[TBL] [Abstract][Full Text] [Related]
18. Elucidation of the relationship of BNIP3 expression to gemcitabine chemosensitivity and prognosis.
Ishida M; Sunamura M; Furukawa T; Akada M; Fujimura H; Shibuya E; Egawa S; Unno M; Horii A
World J Gastroenterol; 2007 Sep; 13(34):4593-7. PubMed ID: 17729412
[TBL] [Abstract][Full Text] [Related]
19. The oncogenic receptor ErbB2 modulates gemcitabine and irinotecan/SN-38 chemoresistance of human pancreatic cancer cells via hCNT1 transporter and multidrug-resistance associated protein MRP-2.
Skrypek N; Vasseur R; Vincent A; Duchêne B; Van Seuningen I; Jonckheere N
Oncotarget; 2015 May; 6(13):10853-67. PubMed ID: 25890497
[TBL] [Abstract][Full Text] [Related]
20. Genome-wide screen identifies PVT1 as a regulator of Gemcitabine sensitivity in human pancreatic cancer cells.
You L; Chang D; Du HZ; Zhao YP
Biochem Biophys Res Commun; 2011 Apr; 407(1):1-6. PubMed ID: 21316338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]